4DMedical Limited (ASX:4DX)
3.640
0.00 (0.00%)
Aug 28, 2026, 4:10 PM AEST
4DMedical Revenue
In the fiscal year ending June 30, 2026, 4DMedical had annual revenue of 7.06M AUD with 20.64% growth. 4DMedical had revenue of 2.85M in the half year ending December 31, 2025, with 259.90% growth.
Revenue
7.06M
Revenue Growth
+20.64%
P/S Ratio
308.02
Revenue / Employee
n/a
Employees
124
Market Cap
2.18B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 7.06M | 1.21M | 20.64% |
| Jun 30, 2025 | 5.85M | 2.10M | 55.91% |
| Jun 30, 2024 | 3.75M | 3.04M | 422.45% |
| Jun 30, 2023 | 718.58K | -335.72K | -31.84% |
| Jun 30, 2022 | 1.05M | 837.32K | 385.90% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cochlear | 2.35B |
| PolyNovo | 149.85M |
| SomnoMed | 114.53M |
| Saluda Medical | 114.04M |
| Aroa Biosurgery | 86.47M |
| Cyclopharm | 34.42M |
| Lumos Diagnostics Holdings | 19.07M |
| EBR Systems | 9.32M |
4DMedical News
- 15 hours ago - 4DMedical Earnings release: H2 2026 - Filings
- 15 hours ago - 4DMedical Annual report: H2 2026 - Filings
- 2 months ago - 4DMedical Transcript: Life Sciences Virtual Investor Forum - Transcripts
- 2 months ago - 4DMedical Transcript: Investor update - Transcripts
- 2 months ago - 4DMedical Press release: Investor update - Filings
- 3 months ago - 4DMedical Transcript: Status update - Transcripts
- 4 months ago - 4DMedical Earnings release: Q3 2026 - Filings
- 4 months ago - 4DMedical Transcript: AI & Technology Virtual Investor Conference - Transcripts